Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Wadsworth

Showing results (131-140 of 137) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 137 results.
The Journal of Infectious Diseases|January 27, 2021
Humanized Transgenic Mice Are Resistant to Chronic Wasting Disease Prions From Norwegian Reindeer and MooseJonathan D F Wadsworth, Susan Joiner, Jacqueline M Linehan, et al.
Journal of Neurology|March 29, 2025
PRNP E146G mutation inherited prion disease: distinctive clinical, pathological and fluid biomarker featuresThomas Coysh, Zane Jaunmuktane, Laszlo L P Hosszu, et al.
JAMA Neurology|February 24, 2016
Clinical Trial Simulations Based on Genetic Stratification and the Natural History of a Functional Outcome Measure in Creutzfeldt-Jakob DiseaseSimon Mead, Matthew Burnell, Jessica Lowe, et al.
Open Biology|December 4, 2015
A systematic investigation of production of synthetic prions from recombinant prion proteinChristian Schmidt, Jeremie Fizet, Francesca Properzi, et al.
Cancer Research|August 17, 2002
ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administrationStephen R Wedge, Donald J Ogilvie, Michael Dukes, et al.
The New England Journal of Medicine|November 15, 2013
A novel prion disease associated with diarrhea and autonomic neuropathySimon Mead, Sonia Gandhi, Jon Beck, et al.
Cancer Research|May 19, 2005
AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancerStephen R Wedge, Jane Kendrew, Laurent F Hennequin, et al.
Pageof 14

Showing results (131-140 of 137) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 137 results.
The Journal of Infectious Diseases|January 27, 2021
Humanized Transgenic Mice Are Resistant to Chronic Wasting Disease Prions From Norwegian Reindeer and MooseJonathan D F Wadsworth, Susan Joiner, Jacqueline M Linehan, et al.
Journal of Neurology|March 29, 2025
PRNP E146G mutation inherited prion disease: distinctive clinical, pathological and fluid biomarker featuresThomas Coysh, Zane Jaunmuktane, Laszlo L P Hosszu, et al.
JAMA Neurology|February 24, 2016
Clinical Trial Simulations Based on Genetic Stratification and the Natural History of a Functional Outcome Measure in Creutzfeldt-Jakob DiseaseSimon Mead, Matthew Burnell, Jessica Lowe, et al.
Open Biology|December 4, 2015
A systematic investigation of production of synthetic prions from recombinant prion proteinChristian Schmidt, Jeremie Fizet, Francesca Properzi, et al.
Cancer Research|August 17, 2002
ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administrationStephen R Wedge, Donald J Ogilvie, Michael Dukes, et al.
The New England Journal of Medicine|November 15, 2013
A novel prion disease associated with diarrhea and autonomic neuropathySimon Mead, Sonia Gandhi, Jon Beck, et al.
Cancer Research|May 19, 2005
AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancerStephen R Wedge, Jane Kendrew, Laurent F Hennequin, et al.
Pageof 14